| abstract |
The invention describes compounds of general formula I, where R is phenyl, piperidin-1-yl or morpholinyl, A is —O—, and R is - (CH) -N (R ") - C (O) - (lower) alkyl , - (CH) -O- (lower) alkyl, - (CH) -O- (CH) -O- (lower) alkyl, (lower) alkyl, - (CH) -morpholinyl, - (CH) -phenyl, - (CH) -N (R "), - (CH) -pyridinyl, - (CH) -CF, - (CH) -2-oxopyrrolidinyl or C-C-cycloalkyl, R" independently of one another hydrogen or lower alkyl, and n is 1 or 2, or A is —N (R ′) -, and R is lower alkyl, C — C cycloalkyl, - (CH) —O— lower .) alkyl, - (CH) -pyridinyl, - (CH) -piperidinyl, - (CH) -phenyl, - (CH) -N (R ") - C (O) - (lower) alkyl, - (CH ) -morpholinyl or - (CH) -N (R "), R ' and R ″ independently of one another is hydrogen or lower alkyl, and n is 1 or 2, or A is —CH—, and R is —N (R ”) - (CH) —O— (lower) alkyl, —N (R "), -S- (lower) alkyl, or R is azetidinyl, pyrrolidinyl or piperidinyl, which are optionally substituted with hydroxy or (lower) alkoxy, or R is morpholinyl, -N (R") - (CH) - (C-C) cycloalkyl, -N (R ") - (CH) -C (O) O- (lower) alkyl, -N (R") - (CH) -C (O) OH , -2-oxopyrrolidinyl, -N (R ") - C (O) O- (lower) alkyl, -O (CH) -O- (lower) alkyl or alkoxy, R" are independently hydrogen or (ness.) alkyl, am is 1, 2 or 3; A is —S—, and R is (ness.) Alkyl, or AR together is piperazinyl substituted by (ness.) Alkyl, —C (O) - (ness.) Alkyl or oxo, or the AR group is piperidinyl substituted ( lower alkoxy or hydroxy group, or AR group means morpholinyl substituted with lower alkyl, or AR group means C-C-cycloalkyl, azetidin-1-yl optionally substituted with hydroxy group or lower alkoxy, or AR group means thiomorpholin-1,1-dioxo, tetrahydropyran or 2-oxa-5-azabicyclo [2.2.1] hept-5-yl, and their pharmaceutically acceptable acid addition salts . It has been found that the compounds of general formula I are ligands of the adenosine receptor. The compounds of the present invention primarily have a high affinity for the adenosine A receptor and can be used to treat diseases mediated by the indicated receptor. |